Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
Revenues
Operating expenses:        
General and administrative 81,483 82,925 150,497 162,768
Total operating expenses 81,483 82,925 150,497 162,768
Loss from operations (81,483) (82,925) (150,497) (162,768)
Gain on fair value adjustment - derivatives 4,000 3,200
Other income (expense):        
Interest expense (67,065) (68,189) (130,951) (132,216)
Amortization - debt discount (12,407) (500) (17,763) (500)
Total other income (expense) (75,472) (68,689) (145,514) (132,716)
Loss before provision for income taxes (156,955) (151,614) (296,011) (295,484)
Net loss (156,955) (151,614) (296,011) (295,484)
Net loss attributable to noncontrolling interest 818 804 1,585 1,625
Net loss attributable to TranBiotec, Inc. $ (156,137) $ (150,810) $ (294,426) $ (293,859)
(Basic and fully diluted) $ (0.001) $ (0.001) $ (0.002) $ (0.003)
Net loss per share        
Weighted average number of common shares outstanding 152,205,625 115,152,177 141,236,262 112,296,916